NMDP breakfast symposium presented Friday December 7, preceding the 2012 ASH Annual Meeting
This content will be available as an online CME activity beginning spring 2013. Check back for details.
Using a didactic and interactive case study approach, attendees will learn practical applications of classification and research data to compare treatment choices for older AML and MDS patients. For AML, how has diagnostic testing changed the timing of therapeutic choices and how should age factor into the decision? For aging MDS patients, how can the data be applied to mitigate risk and optimize the benefit between new drugs, transplantation, and the combination treatment approaches? How will new research studies affect the options for Medicare-eligible patients?
Gail Roboz, M.D
Associate Professor of Medicine, Weill Cornell Medical College
Associate Attending Physician, NewYork-Presbyterian Hospital
Frederick Appelbaum, M.D.
Executive Director, Seattle Cancer Care Alliance
Clinical Research Division, Director, Fred Hutchinson Cancer Research Center
Professor, Medical Oncology Division, University of Washington School of Medicine
David Steensma, M.D.
Associate Professor, Department of Medicine, Harvard Medical School
Attending Physician, Hematologic Oncology, Dana-Farber Cancer Institute
Attending Physician, Medicine, Brigham And Women's Hospital
Stephen Forman, M.D.
Chair, Hematology & Hematopoietic Cell Transplantation
Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation
Co-leader, Hematologic Malignancies Program, Comprehensive Cancer Center
Clinical Director, Cancer Immunotherapeutics & Tumor Immunology, City of Hope
Willis Navarro, M.D.
Medical Director, National Marrow Donor Program
Associate Clinical Professor of Medicine, University of California San Francisco
If you have any questions regarding this activity, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail email@example.com.